Verastem, Inc., a developing-stage biopharmaceutical company focused on developing and commercializing life-enhancing drugs for cancer patients. The company is headquartered in Needham, Massachusetts.
| Revenue (TTM) | $30.91M |
| Gross Profit (TTM) | $26.31M |
| EBITDA | $-169.40M |
| Operating Margin | -236.50% |
| Return on Equity | -1480.00% |
| Return on Assets | -61.10% |
| Revenue/Share (TTM) | $0.45 |
| Book Value | $0.74 |
| Price-to-Book | 8.29 |
| Price-to-Sales (TTM) | 15.34 |
| EV/Revenue | 11.23 |
| EV/EBITDA | -0.19 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -78.60% |
| Shares Outstanding | $87.84M |
| Float | $75.00M |
| % Insiders | 0.67% |
| % Institutions | 87.78% |
Volatility is currently contracting